Pliant Therapeutics (PLRX) Enterprise Value (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Enterprise Value of -$170.9 million for Q1 2026, up 44.09% year-over-year from -$118.6 million in Q1 2025, and up 10.5% quarter-over-quarter from -$190.9 million in Q4 2025.
Pliant Therapeutics (PLRX) Enterprise Value (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Enterprise Value for 8 consecutive years, with -$170.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 44.09% year-over-year to -$170.9 million; the TTM figure through Mar 2026 stood at -$170.9 million (up 44.09% YoY), while the FY2025 annual figure was -$190.9 million, up 46.32% from the prior year.
- Enterprise Value advanced to -$170.9 million in Q1 2026 per PLRX's latest filing, from -$190.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$163.6 million in Q2 2022 and bottomed at -$577.3 million in Q1 2023.
- Historically, Enterprise Value has averaged -$355.0 million across 5 years, with a median of -$355.7 million in 2024.
- Annual changes were most pronounced in 2023 — Enterprise Value tumbled 239.35% — and 2025, when it soared 46.32%.
- Pliant Therapeutics' Enterprise Value stood at -$331.2 million in 2022, then slumped by 49.23% to -$494.2 million in 2023, then climbed by 28.03% to -$355.7 million in 2024, then jumped by 46.32% to -$190.9 million in 2025, then increased by 10.5% to -$170.9 million in 2026.
- Business Quant data shows PLRX's Enterprise Value at -$170.9 million in Q1 2026, -$190.9 million in Q4 2025, and -$241.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Pliant Therapeutics | 70.59 Mn | 70.59 Mn | - | -158.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -158.10 Mn |
| Mar 31, 2026 | -170.89 Mn |
| Dec 31, 2025 | -190.94 Mn |
| Sep 30, 2025 | -241.80 Mn |
| Jun 30, 2025 | -262.87 Mn |
| Mar 31, 2025 | -305.65 Mn |
| Dec 31, 2024 | -355.72 Mn |
| Sep 30, 2024 | -404.51 Mn |
| Jun 30, 2024 | -436.61 Mn |
| Mar 31, 2024 | -482.39 Mn |
| Dec 31, 2023 | -494.25 Mn |
| Sep 30, 2023 | -523.61 Mn |
| Jun 30, 2023 | -555.16 Mn |
| Mar 31, 2023 | -577.31 Mn |
| Dec 31, 2022 | -331.19 Mn |
| Sep 30, 2022 | -360.24 Mn |
| Jun 30, 2022 | -163.60 Mn |
| Mar 31, 2022 | -178.28 Mn |
| Dec 31, 2021 | -200.60 Mn |
| Sep 30, 2021 | -221.04 Mn |